There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according ...

A target trial emulation study compared risk for depression among older adults with type 2 diabetes initiating treatment with ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...